Courage to innovate
Change the future

OBI Pharma’s Obrion® ADC Technology Platform Wins Product Innovation of the Year at the 2026 Taiwan BIO Awards

Taiwan-Originated ADC Platform Recognized for Innovation, Commercialization Potential, and Global Market Advancement TAIPEI, Taiwan, July 6, 2026 — OBI Pharma, Inc. (4174.TWO) today announced that its “Obrion® ADC Technology Platform: Global Commercial Licensing of Site-Specific ADC Technology and Applications in Bispecific Dual-Payload ADCs” has received the Product Innovation of the Year Award at the 2026 […]

OBI Holds 2026 Annual Shareholders’ Meeting
Capturing Global Opportunities in Next-Generation ADCs with Its Proprietary Obrion® Platform to Advance Bispecific Dual-Payload ADCs and International Licensing Strategy

OBI Presents Three Featured Talks at the 2026 World ADC Summit South Korea
Highlighting GlycOBI® and Dual-Payload ADC Technologies

Taipei, Taiwan, June 11, 2026 —OBI Pharma, Inc. (4174.TWO), a leader in innovative biopharmaceuticals, successfully delivered three featured presentations at the 5th World ADC Summit South Korea in Seoul. The presentations highlighted major advancements in the company’s proprietary Obrion® technology. These include GlycOBI® glycan-conjugation, GlycOBI DUO® dual-payload platforms, and next-generation analytical and manufacturing processes. The global […]

OBI Announces US FDA Registration and Activation of HYProtecan™ Type II Drug Master File
Supporting Obrion Engine™ ADC Technologies and Enhancing Regulatory Efficiency

Taipei, Taiwan, April 24, 2026 — OBI Pharma (4174.TWO) today announced that it has received an acknowledgement letter from the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) confirming that the Type II Drug Master File (DMF) for HYProtecanTM is active. The DMF has been included in the FDA’s publicly available […]

OBI is featured in the Bioconjugate Insights on Bispecific and Dual-Payload ADC Design Strategies
Focusing on Approaches to Address Tumor Heterogeneity and Drug Resistance

OBI Pharma (4174.TWO) announced that its Chief Scientific Officer, Dr. Ya-Chi Chen, was recently featured in an interview with the prestigious international media platform Bioconjugate Insights, where she shared the company’s innovative strategies for next-generation antibody–drug conjugates (ADCs). In the interview, Dr. Chen provided insights into how rational design approaches can address key clinical challenges, […]

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI® Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion™ ADC enabling technologies.

Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI’s novel Obrion™ ADC enabling technologies(GlycOBI® and GlycOBI DUO®). Taipei, Taiwan. April 15, 2026 – OBI Pharma, Inc. (TPEx: 4174. TWO) today announced its presence at AACR 2026, highlighted by ten […]